{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:42:26Z","timestamp":1740159746483,"version":"3.37.3"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007352","name":"Staatssekretariat f\u00fcr Bildung, Forschung und Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jgo.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T13:32:15Z","timestamp":1663507935000},"page":"101372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25\/14]"],"prefix":"10.1016","volume":"14","author":[{"given":"Ursula","family":"Hasler-Strub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"Thuerlimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Rochlitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Aebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochstrasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Gick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Baertschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Greuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens B.","family":"Caspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ruhstaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"International Agency for Research on Cancer","key":"10.1016\/j.jgo.2022.09.001_bb0005"},{"key":"10.1016\/j.jgo.2022.09.001_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jgo.2012.08.002","article-title":"Treatment of breast cancer in the elderly: a prospective, population-based Swiss study","volume":"4","author":"Joerger","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2022.09.001_bb0015","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1200\/JCO.18.02217","article-title":"Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4\/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis","volume":"37","author":"Howie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2022.09.001_bb0020","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2022.09.001_bb0025","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/S1470-2045(11)70383-7","article-title":"Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)","volume":"13","author":"Biganzoli","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2022.09.001_bb0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.jgo.2022.09.001_bb0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1634\/theoncologist.2013-0282","article-title":"Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer","volume":"19","author":"Muss","year":"2014","journal-title":"Oncologist."},{"key":"10.1016\/j.jgo.2022.09.001_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","article-title":"Eribulin -- a review of preclinical and clinical studies","volume":"81","author":"Swami","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2022.09.001_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-014-2923-9","article-title":"Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer","volume":"146","author":"McIntyre","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2022.09.001_bb0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.clbc.2014.04.004","article-title":"Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer","volume":"14","author":"Wilks","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jgo.2022.09.001_bb0055","first-page":"741","article-title":"Psychometric evaluation of the functional assessment of cancer therapy\/gynecologic oncology group-neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jgo.2022.09.001_bb0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2022.09.001_bb0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2022.09.001_bb0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clbc.2019.09.007","article-title":"Phase II study of eribulin mesylate administered biweekly in patients with human epidermal growth factor receptor-2-negative metastatic breast cancer","volume":"20","author":"Smith","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jgo.2022.09.001_bb0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s40064-016-1833-1","article-title":"A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer","volume":"5","author":"Takashima","year":"2016","journal-title":"Springerplus."},{"key":"10.1016\/j.jgo.2022.09.001_bb0080","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10549-018-4778-y","article-title":"Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan","volume":"170","author":"Rau","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2022.09.001_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.breast.2016.12.017","article-title":"Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"32","author":"Maeda","year":"2017","journal-title":"Breast."},{"key":"10.1016\/j.jgo.2022.09.001_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clbc.2018.12.012","article-title":"Phase II, multicenter, single-arm trial of Eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2-negative metastatic breast cancer: the MERIBEL study","volume":"19","author":"Ortega","year":"2019","journal-title":"Clin Breast Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682200220X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682200220X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:42:49Z","timestamp":1724758969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187940682200220X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S187940682200220X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2022.09.001","relation":{},"ISSN":["1879-4068"],"issn-type":[{"type":"print","value":"1879-4068"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25\/14]","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101372"}}